Healthy volunteers test new MASH drug in early safety trial
NCT ID NCT07331545
First seen Jan 12, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This early-stage study tests QL2401, a potential treatment for a liver condition called MASH, in 70 healthy Chinese adults. Participants receive either the drug or a placebo to check for side effects and how the body processes it. The goal is safety and dosing information, not treatment. Healthy volunteers aged 18-45 with normal weight can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.